Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
Alzheimer’s disease (AD) is a commonly occurring neurodegenerative disease in the advanced-age population, with a doubling of prevalence for each 5 years of age above 60 years. In the past two decades, there has been a sustained effort to find suitable biomarkers that may not only aide with the diag...
Main Authors: | Syed Haris Omar, John Preddy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/10/3/63 |
Similar Items
-
From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer’s Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients
by: Ioanna Tsantzali, et al.
Published: (2021-10-01) -
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
by: Giovanni Bellomo, et al.
Published: (2021-03-01) -
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia
by: Franc Llorens, et al.
Published: (2017-09-01) -
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
by: Donovan A. McGrowder, et al.
Published: (2021-02-01) -
Effect of long‐term storage in biobanks on cerebrospinal fluid biomarker Aβ1‐42, T‐tau, and P‐tau values
by: Eline A.J. Willemse, et al.
Published: (2017-01-01)